Valuation
- Market cap
- 379,630,000
- Revenue TTM
- $0
- Net income TTM
- $-42,700,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 7,348,600
- Avg volume
- 1,785,852
- Day's range
- $0.24 – $0.29
- Shares out
- 1,518,518,000
- Stochastic %K
- 57%
- Beta
- 1.50
- Analysts
- Strong Buy
- Price target
- $4.00
Company profile
CytoDyn Inc., a clinical-stage biotechnology company, develops treatments for multiple therapeutic indications. The company develops leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19. Its leronlimab completed phase 2 development for the treatment of micro-satellite stable colorectal cancer, and solid tumors in oncology, such as metastatic t...
Show more
CytoDyn Inc., a clinical-stage biotechnology company, develops treatments for multiple therapeutic indications. The company develops leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19. Its leronlimab completed phase 2 development for the treatment of micro-satellite stable colorectal cancer, and solid tumors in oncology, such as metastatic triple-negative breast cancer. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 360 980 8524
- Website
- https://www.cytodyn.com
- Address
- 1111 Main Street, Suite 660, Vancouver, United States
Latest news
No headlines yet.
